FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors


Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15Mono- and di-peg il-10 production; and uses
22015001159001/08/15Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015014733705/28/15 new patent  Crystalline anti-human il-23 antibodies
62015014824605/28/15 new patent  Surface anchored light chain bait antibody display system
72015014832705/28/15 new patent  Substituted pyridine spleen tyrosine kinase (syk) inhibitors
82015013998605/21/15Ilt3 binding molecules and uses therefor
92015014142805/21/15Trka kinase inhibitors, compositions and methods thereof
102015014144405/21/15N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
112015012644305/07/15Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
122015012649305/07/15Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
132015011939404/30/15Insulin-like growth factor-1 receptor inhibitors
142015011186604/23/15Cyclic amine substituted heterocyclic cetp inhibitors
152015011187704/23/15Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
162015011191404/23/15Spirolactam cgrp receptor antagonists
172015010445304/16/15Fdf03 antibodies and uses thereof
182015010446504/16/15Il-19 as a biomarker of tslp treatment
192015010531704/16/15Glucose-responsive insulin conjugates
202015010535404/16/15Heterocyclic aspartyl protease inhibitors
212015009989104/09/15Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
222015009971504/09/15Formulations of acadesine
232015009971904/09/15Cathepsin cysteine protease inhibitors
242015009972904/09/15Inhibitors of the renal outer medullary potassium channel
252015009977104/09/15Pyridine cgrp receptor antagonists
262015009339804/02/15Methods and compositions for treating or preventing cancer
272015008390603/26/15Biomarkers for monitoring intervention therapies for diabetes
282015008764103/26/15Heterocyclic cgrp receptor antagonists
292015008783203/26/15Process for making beta 3 agonists and intermediates
302015007899603/19/15Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
312015007903103/19/15Use of pegylated il-10 to treat cancer
322015008059803/19/15Asymmetric synthesis for preparing fluoroleucine alkyl esters
332015006419203/05/15Mammalian cell surface antigens; related reagents
342015005619102/26/15Igf1 biomarker for igf1r inhibitor therapy
352015005122702/19/15Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
362015005124802/19/15Imidazolyl methyl piperidine t-type calcium channel antagonists
372015004425002/12/15Vaccines against clostridium difficile comprising recombinant toxins
382015004534602/12/15Selective glycosidase inhibitors and uses thereof
392015004557502/12/15Process for preparing fluoroleucine alkyl esters
402015003849002/05/15Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
412015003849802/05/15Thrombin inhibitors
422015003850202/05/15Isoxazolopyridine orexin receptor antagonists
432015003870702/05/15Process for making cgrp receptor antagonists
442015003171301/29/15Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
452015003171601/29/15Piperidinone carboxamide azaindane cgrp receptor antagonists
462015003189101/29/15Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
472015002080601/22/15Dry powder inhaler for delivering multipe agglomerate formulations
482015002395201/22/15Anti-addl monoclonal antibody and uses thereof
492015002407101/22/15Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
502015002504601/22/15Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
512015001768601/15/15Methods for reducing mannosyltransferase activity in lower eukaryotes
522015001839901/15/15Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
532015001056401/08/15Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
542015000460801/01/15Monocyte-derived nucleic acids and related compositions and methods
552015000533001/01/15Piperidinone carboxamide azaindane cgrp receptor antagonists
562014037726012/25/14Protective vaccine based on staphylococcus aureus sa2074 protein
572014037849312/25/14Fused bicyclic oxazolidinone cetp inhibitor
582014037002512/18/14Uses of mammalian cytokines and agonists; related reagents
592014037113812/18/14Inhibitors of hepatitis c virus replication
602014034997211/27/14Substituted pyrimidines
612014034884111/27/14Anti-gitr antibodies
622014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
632014035000211/27/14Imidazopyridin-2-one derivatives
642014034307111/20/14Compositions and methods for treating cancer
652014033619611/13/14Phosphoric acid salts of sitagliptin
662014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
672014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
682014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
692014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
702014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
712014027501709/18/14Cgrp receptor antagonists
722014025681809/11/14Nano-suspension process
732014024428908/28/14Cold storage system for storing pharmaceutical product containers
742014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
752014023430108/21/14Modulation of pilr to treat immune disorders
762014023553708/21/14N-glycosylated insulin analogues
772014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
782014022722308/14/14Pegylated interleukin-10
792014022725008/14/14Stable formulations of antibodies to tslp
802014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
812014022729208/14/14Anti-mcam antibodies and associated methods of use
822014022002708/07/141d05 pcsk9 antagonists
832014022138308/07/14Cetp inhibitors
842014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
852014020656307/24/14Biomarkers for psoriasis
862014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
872014020664107/24/14Remedy
882014020666507/24/14Selective glycosidase inhibitors and uses thereof
892014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
902014020671507/24/14Preparation and use of compounds as protease inhibitors
912014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
922014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
932014017015406/19/14Engineered anti-il-23r antibodies
942014017065806/19/14Mammalian cytokines; related reagents
952014017143706/19/14Oxazole derivatives useful as inhibitors of faah
962014017145606/19/14Fused tricyclic compounds as mtor inhibitors
972014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
982014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
992014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
1002014014744205/29/14Use of il-23 antagonists for treatment of infection
1012014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
1022014014095405/22/14Methods of modulating cytokine activity; related reagents
1032014014101205/22/14Engineered anti-tslp antibody
1042014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
1052014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
1062014014211505/22/14Inhibitors of the renal outer medullary potassium channel
1072014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
1082014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
1092014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
1102014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
1112014011291904/24/14Interleukin-10 antibodies
1122014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1132014010588704/17/14Methods for modulating il-33 activity
1142014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
1152014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
1162014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
1172014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
1182014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
1192014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
1202014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
1212014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1222014004574602/13/14Antidiabetic tricyclic compounds
1232014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1242014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
1252014003762702/06/14Modulation of pilr receptors to treat microbial infections
1262014003894202/06/14Rorgammat inhibitors
1272014003897002/06/14Bridged and fused antidiabetic compounds
1282014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
1292014003076001/30/14Pavec
1302014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
1312014003134901/30/14Inhibitors of the renal outer medullary potassium channel
1322014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1332014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1342013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
1352013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
1362013032323912/05/13Modulation of pilr receptors to treat sepsis
1372013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
1382013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1392013032448312/05/13Mammalian cell surface antigens; related reagents
1402013032461012/05/13Cathepsin cysteine protease inhibitors
1412013032472812/05/13Process for the preparation of an orexin receptor antagonist
1422013031635411/28/13Mammalian cytokine; related reagents
1432013029627811/07/13Diazeniumdiolate derivatives
1442013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1452013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1462013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1472013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1482013025167709/26/13Genetic markers associated with interferon-alpha response
1492013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1502013023751809/12/13Novel compounds that are erk inhibitors
1512013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1522013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1532013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1542013021657508/22/13Recombinant subunit dengue virus vaccine
1552013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1562013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1572013021776608/22/13Formulations for cathepsin k inhibitors
1582013020306008/08/13Mammalian genes; related reagents
1592013018927807/25/13Antagonists of pcsk9
1602013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1612013015672906/20/13Mammalian receptor proteins; related reagents and methods
1622013015677106/20/13Fdf03 antibodies and uses thereof
1632013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1642013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1652013013104105/23/13Spirocyclic compounds
1662013013104205/23/13Spiroxazolidinone compounds
1672013012200905/16/13Engineered anti-il-23p19 antibodies
1682013012320005/16/13Mammalian cell surface antigens; related reagents
1692013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1702013011522305/09/13Antagonists of pcsk9
1712013011623105/09/13Tyrosine kinase inhibitors
1722013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1732013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1742013007139003/21/13Method for preparing antibodies having improved properties
1752013006481703/14/13Engineered anti-il-23r antibodies
1762013005985003/07/13Aza-indole derivatives useful as modulators of faah
1772013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1782013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1792013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1802013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1812013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1822013003531202/07/13Cathepsin cysteine protease inhibiors
1832013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1842013001804801/17/13Oxazole derivatives useful as modulators of faah
1852013001252601/10/13Oxazole derivatives useful as modulators of faah
1862013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1872013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1882012032967912/27/12Eukaryotic cell display systems
1892012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1902012031620012/13/12Pyridone derivatives
1912012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1922012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1932012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1942012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1952012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1962012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1972012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1982012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1992012019690108/02/12Tertiary amide orexin receptor antagonists
2002012019070107/26/12Renin inhibitors
2012012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
2022012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
2032012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2042012016415806/28/12Anti-addl monoclonal antibody and use thereof
2052012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2062012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2072012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
2082012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
2092012014275206/07/12Hiv protease inhibitors
2102012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
2112012012162405/17/12Hepatitis c virus ns3 protease inhibitors
2122012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
2132012012150805/17/12Radiolabeled cgrp antagonists
2142012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
2152012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2162012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2172012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2182012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
2192012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
2202012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
2212012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
2222012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2232012008348304/05/12Inhibitors of hepatitis c virus replication
2242012008267904/05/12Antagonists of pcsk9
2252012008268004/05/12Antagonists of pcsk9
2262012007679903/29/12Antagonists of pcsk9
2272012007796403/29/12Antagonists of pcsk9
2282012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2292012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2302012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2312012003521402/09/12Renin inhibitors
2322012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2332012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2342012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2352012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2362012002107401/26/12P2x3, receptor antagonists for treatment of pain
2372012002194801/26/12Surface display of whole antibodies in eukaryotes
2382012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2392012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2402012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2412012000958001/12/12Methods for quantitating small rna molecules
2422012001019301/12/12Cgrp receptor antagonists
2432012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2442012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2452012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2462012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2472011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2482011030107912/08/11Neuromedin u receptor agonists and uses thereof
2492011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE